Antivector and antitransgene host responses in gene therapy

N. R. Hackett, S. M. Kaminsky, D. Sondhi, Ronald Crystal

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Current viral gene therapy vectors effectively transfer genes in vivo at the price of eliciting innate and acquired host responses against the vector and/or transgene. Antigens present in the viral vector and the expression of the transgene both cause cellular and humoral immune responses dependent on the viral vector, the route of administration, and the genotype and infection history of the host. In general, adenoviral vectors cause strong immune responses, which result in only transient expression of the therapeutic gene. Adeno-associated virus and retrovirus vectors elicit weaker immune responses and can therefore result in long-term gene transfer and expression. Methods to avoid host responses, including modification of viral vector and immunosuppression of the host, can increase the longevity and efficiency of gene transfer.

Original languageEnglish
Pages (from-to)376-382
Number of pages7
JournalCurrent Opinion in Molecular Therapeutics
Volume2
Issue number4
Publication statusPublished - 12 Sep 2000
Externally publishedYes

Fingerprint

Transgenes
Genetic Therapy
Gene Expression
Dependovirus
Viral Genes
Retroviridae
Humoral Immunity
Cellular Immunity
Immunosuppression
Genes
Genotype
Antigens
Infection
Therapeutics

Keywords

  • Adeno-associated virus
  • Adenovirus
  • Antibodies
  • Gene therapy
  • Immunity
  • Retrovirus

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery
  • Genetics(clinical)

Cite this

Antivector and antitransgene host responses in gene therapy. / Hackett, N. R.; Kaminsky, S. M.; Sondhi, D.; Crystal, Ronald.

In: Current Opinion in Molecular Therapeutics, Vol. 2, No. 4, 12.09.2000, p. 376-382.

Research output: Contribution to journalArticle

Hackett, NR, Kaminsky, SM, Sondhi, D & Crystal, R 2000, 'Antivector and antitransgene host responses in gene therapy', Current Opinion in Molecular Therapeutics, vol. 2, no. 4, pp. 376-382.
Hackett, N. R. ; Kaminsky, S. M. ; Sondhi, D. ; Crystal, Ronald. / Antivector and antitransgene host responses in gene therapy. In: Current Opinion in Molecular Therapeutics. 2000 ; Vol. 2, No. 4. pp. 376-382.
@article{26747647abec422db7960da38aa831b3,
title = "Antivector and antitransgene host responses in gene therapy",
abstract = "Current viral gene therapy vectors effectively transfer genes in vivo at the price of eliciting innate and acquired host responses against the vector and/or transgene. Antigens present in the viral vector and the expression of the transgene both cause cellular and humoral immune responses dependent on the viral vector, the route of administration, and the genotype and infection history of the host. In general, adenoviral vectors cause strong immune responses, which result in only transient expression of the therapeutic gene. Adeno-associated virus and retrovirus vectors elicit weaker immune responses and can therefore result in long-term gene transfer and expression. Methods to avoid host responses, including modification of viral vector and immunosuppression of the host, can increase the longevity and efficiency of gene transfer.",
keywords = "Adeno-associated virus, Adenovirus, Antibodies, Gene therapy, Immunity, Retrovirus",
author = "Hackett, {N. R.} and Kaminsky, {S. M.} and D. Sondhi and Ronald Crystal",
year = "2000",
month = "9",
day = "12",
language = "English",
volume = "2",
pages = "376--382",
journal = "Current Opinion in Molecular Therapeutics",
issn = "1464-8431",
publisher = "Current Drugs Ltd.",
number = "4",

}

TY - JOUR

T1 - Antivector and antitransgene host responses in gene therapy

AU - Hackett, N. R.

AU - Kaminsky, S. M.

AU - Sondhi, D.

AU - Crystal, Ronald

PY - 2000/9/12

Y1 - 2000/9/12

N2 - Current viral gene therapy vectors effectively transfer genes in vivo at the price of eliciting innate and acquired host responses against the vector and/or transgene. Antigens present in the viral vector and the expression of the transgene both cause cellular and humoral immune responses dependent on the viral vector, the route of administration, and the genotype and infection history of the host. In general, adenoviral vectors cause strong immune responses, which result in only transient expression of the therapeutic gene. Adeno-associated virus and retrovirus vectors elicit weaker immune responses and can therefore result in long-term gene transfer and expression. Methods to avoid host responses, including modification of viral vector and immunosuppression of the host, can increase the longevity and efficiency of gene transfer.

AB - Current viral gene therapy vectors effectively transfer genes in vivo at the price of eliciting innate and acquired host responses against the vector and/or transgene. Antigens present in the viral vector and the expression of the transgene both cause cellular and humoral immune responses dependent on the viral vector, the route of administration, and the genotype and infection history of the host. In general, adenoviral vectors cause strong immune responses, which result in only transient expression of the therapeutic gene. Adeno-associated virus and retrovirus vectors elicit weaker immune responses and can therefore result in long-term gene transfer and expression. Methods to avoid host responses, including modification of viral vector and immunosuppression of the host, can increase the longevity and efficiency of gene transfer.

KW - Adeno-associated virus

KW - Adenovirus

KW - Antibodies

KW - Gene therapy

KW - Immunity

KW - Retrovirus

UR - http://www.scopus.com/inward/record.url?scp=0033844756&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033844756&partnerID=8YFLogxK

M3 - Article

VL - 2

SP - 376

EP - 382

JO - Current Opinion in Molecular Therapeutics

JF - Current Opinion in Molecular Therapeutics

SN - 1464-8431

IS - 4

ER -